Clinical Trials
31 trialsNCT05149755 2026-05-19
Evolutâ„¢ EXPAND TAVR II Pivotal Trial
Medtronic Cardiovascular
Phase NA Active not recruiting
NCT07581184 2026-05-12
BActinium-1
Aktis Oncology, Inc.
Phase 1 Recruiting
NCT07020117 2026-04-21
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology, Inc.
Phase 1 Recruiting
NCT07406724 2026-02-12
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT07137819 2025-08-22
EXACT-1
Aresus Pharma GmbH
Phase 3 Recruiting
NCT05904236 2025-04-08
ICVB-1042
IconOVir Bio
Phase 1 Terminated
NCT05918783 2025-02-11
Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer
Impact Biotech Ltd
Phase 1 Recruiting
NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
NCT04662320 2024-12-05
PHONES
Checkpoint Surgical Inc.
Phase NA Active not recruiting
NCT03250299 2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
Phase 1 Terminated
NCT06305910 2024-03-12
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Phase 1 Recruiting
NCT02193503 2023-09-28
MVX-ONCO-1 in Patients With Solid Tumor
Maxivax SA
Phase 1 Active not recruiting
NCT04046250 2023-08-25
TK112690
Tosk, Inc.
Phase 2 Completed
NCT04642937 2023-01-27
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
OX2 Therapeutics
Phase 1 Unknown
NCT05673538 2023-01-10
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1 Unknown
NCT00828854 2022-06-30
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
Syndax Pharmaceuticals
Phase 2 Completed
NCT01851772 2021-01-12
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Xoft, Inc.
Phase NA Completed
NCT04423380 2020-06-09
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1 Unknown
NCT00415246 2019-11-22
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
Ipsen
Phase 3 Terminated
NCT01892293 2019-01-10
CT Antigen TCR-Engineered T Cells for Myeloma
Adaptimmune
Phase 1/2 Terminated
NCT03053635 2018-08-20
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
Theralase® Technologies Inc.
Phase 1 Completed
NCT01154140 2017-11-06
PROFILE 1014
Pfizer
Phase 3 Completed
NCT00171964 2017-06-01
Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
Novartis
Phase 4 Completed
NCT02587819 2016-04-14
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
Biosceptre
Phase 1 Completed
NCT01929200 2015-05-22
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT01045187 2012-08-01
Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer
Xoft, Inc.
Phase NA Completed
NCT00874042 2012-07-23
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00305929 2010-06-02
Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure
STEBA France
Phase 2 Completed
NCT00312442 2010-06-02
Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy
STEBA France
Phase 2/3 Terminated
NCT00805636 2010-05-12
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
Aposense Ltd.
Phase 2 Unknown